Upcoming Deadlines

JuMP Undergraduate Summer Studentship
2013 Intake
March 15, 2013 
(Start May 1 2013)
Joint Motion Trainee Program
2013-14 Intake
June 1, 2013
(Start Sept 1 2013)

Upcoming JuMP Events

Seminar Speaker Series:
Auditorium C UH, 10am
Dates:
February 19th, 2013
March 19th, 2013
April 16th, 2013
June 17th, 2013
MSK Annual Retreat
May 8 & 9, 2013
ICHIL Course Module 2: Innovation & Commercialization
CANCELLED for 2012

Also of interest:

Upcoming Conferences

 

Bone and Joint Injury and Repair Conference

Thursday January 16 & 17, 2014

London Convention Centre


The Joint Motion Program (JuMP) is a CIHR Strategic Training Program in Musculoskeletal Health Research and Leadership. Trainees have the unique opportunity to participate in cutting-edge transdisciplinary research and knowledge translation, while gaining the leadership skills and experience that are essential for scientific progress in the 21st century. JuMP trains leaders who can meet the upcoming challenges in musculoskeletal health research and who will significantly improve the health, mobility and quality of life of Canadians.

Joint Motion Program News

In Memorium - Dr. Jim Roth

It is with great sadness that we share with you that Dr. Jim Roth, Chair/Chief, Division of Orthopaedic Surgery, Department of Surgery, Schulich Medicine & Dentistry has passed away.

Dr. Roth was a beloved and renowned physician and a very proud Western alumnus.  Read More...

We have the "Best of the Best"!

 

Matt Teeter

Dan Langohr

IMPORTANT: 

The next competition deadline for the Joint Motion Trainee Program is June 1st, 2013 for a September 1st, 2013 Program Intake.

Contact the Program Coordinator if you have any questions.

****

CIHR Guidebook for New Principle Investigators

 

Funding Opportunities

****

Pilot and Feasibility Clinical Research Grants in Arthritis and Musculoskeletal and Skin Diseases (R21)
PAR-10-282

Submission Dates: July 2, 2012; Nov 1, 2012, March 1, 2013,  July 1, 2013

encourages exploratory/developmental clinical research related to the prevention or treatment of arthritis and musculoskeletal and skin diseases, conditions, and/or injuries. The Pilot and Feasibility Clinical Research Grants Program is designed to allow initiation of exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to gather critical preliminary data in support of a future, planned clinical trial.  They can include testing new or prevention strategies, a new intervention, or unique combinations of therapies.  A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice.

Direct costs are limited to $275,000 over an R21 two-year period

****
Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)

PAR-11-216

Submission Dates:  July 11, 2012; November 13, 2012; March 13, 2013; July 11, 2013; November 13, 2013; March 13, 2014, by 5:00 PM local time of applicant organization.

intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Center and/or Cooperative Groups.

All awards are for up to $500,000 in Direct Costs over 2 years.

 

 


A CIHR Training Program in Musculoskeletal Health Research and Leadership